<p>Last week, the <a href="https://www.biospace.com/article/fda-approves-lilly-s-zepbound-for-chronic-weight-management/" target="_blank" rel="noopener noreferer">FDA approved Eli Lilly&#39;s obesity drug Zepbound</a>, creating an <a href="https://www.biospace.com/article/lilly-s-zepbound-vs-novo-s-wegovy-a-two-horse-race-has-officially-arrived/" target="_blank" rel="noopener noreferer">anticipated intense competition</a> between it and Novo Nordisk&#39;s <a href="https://www.biospace.com/article/novo-builds-wegovy-s-cardio-case-with-much-anticipated-data-drop/" target="_blank" rel="noopener noreferer">Wegovy</a>. BioSpace&#39;s Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class.</p>
<p>Plus, a quick recap on Valneva, the <a href="https://www.biospace.com/article/valneva-gets-fda-s-first-chikungunya-vaccine-approval/">FDA&#39;s first Chikungunya vaccine approval</a>.</p>

Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.